FENtrepid: A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - Sep 18, 2026 - P3 | N=985 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Feb 2027 ➔ Jul 2027
Trial completion date • CNS Disorders • Multiple Sclerosis
|